程序性死亡受体-1及其配体在恶性肿瘤中的研究进展

doi:10.3760/cma.j.issn.1673422X.2015.05.010

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (5): 358-360.doi: 10.3760/cma.j.issn.1673422X.2015.05.010

程序性死亡受体-1及其配体在恶性肿瘤中的研究进展

安徽医科大学第一附属医院肿瘤内科

出版日期:2015-05-08 发布日期:2015-05-12
通讯作者: 孙国平 sunguoping@ahmu.edu.cn

Research update on PD1 and its ligand PDL1 in malignant tumor

Department of Oncology, First Affiliated Hospital of Anhui Medical University

Online:2015-05-08 Published:2015-05-12
Contact: Sun Guoping sunguoping@ahmu.edu.cn

摘要/Abstract

摘要： 程序性死亡配体-1(PD-L1)是新发现的B7家族的成员，与其受体程序性死亡受体-1（PD-1)结合后对免疫应答发挥负性调节作用。PD-1及PD-L1在正常组织及癌组织中的分布存在差异，有可能为恶性肿瘤的免疫治疗提供新的方法。

邵婧怡, 孙国平. 程序性死亡受体-1及其配体在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2015, 42(5): 358-360.

SHAO Jing-Yi, SUN Guo-Ping. Research update on PD1 and its ligand PDL1 in malignant tumor[J]. Journal of International Oncology, 2015, 42(5): 358-360.

［1］ Gong AY, Zhou R, Hu G, et al. MicroRNA513 regulates B7H1 translation and is involved in IFNγinduced B7H1 expression in cholangiocyte［J］. J Immunol, 2009, 182(3):13251333. ［2］ Chen J, Feng Y, Lu LB, et al. Interferonγinduced PDL1 surface expression on human oral squamous carcinoma via PKD2 signal pathway［J］. Immunobiology, 2012, 217(4):385393. ［3］ Azuma K, Ota K, Kawahara A, et al. Association of PDL1 overexpression with activating EGFR mutations in surgically resected nonsmall cell lung cancer［J］. Ann Oncol, 2014, 25(10):19351940. ［4］ Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA200/ZEB1 axis control of tumour cell PDL1 expression andintratumoral immunosuppression［J］. Nat Commun, 2014, 28(5):5241. ［5］ Mu CY, Huang JA, Chen Y, et al. High expression of PDL1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation［J］. Med Oncol, 2011, 28(3):682688. ［6］陈成, 穆传勇, 翟秋霞, 等. PDL1分子在肺癌细胞株上的表达及其生物学意义［J］. 中国肺癌杂志, 2009, 12(8):859863. ［7］ Wang L, Ma Q, Chen X, et al. Clinical significance of b7h1 and b71 expression in pancreatic carcinoma［J］. World J Surg, 2010, 34(5):10591065. ［8］ Zhang Y, Zhang J, Xu K, et al. PTEN/PI3K/mTOR/B7H1 signaling pathway regulates cell progression and immunoresistance in pancreatic cancer［J］. Hepatogastroenterology, 2013, 60(127):17661772. ［9］ Song X, Liu J, Lu Y, et al. Overexpression of B7H1 correlates with malignant cell proliferation in pancreatic cancer［J］. Oncol Rep, 2014, 31(3):11911198. ［10］ Okudaira K, Hokari R, Tsuzuki Y, et al. Blockade of B7H1 or B7DC induces an antitumor effect in a mouse pancreatic cancer model［J］. Int J Oncol, 2009, 35(4):741749. ［11］ Geng Y, Wang H, Lu C, et al. Expression of costimulatory molecules B7H1, B7H4 and Foxp3+ Tregs in gastric cancer and its clinical significance［J］. Int J Clin Oncol, 2015, 20(2): m273281. ［12］ Hua D, Sun J, Mao Y, et al. B7H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma［J］. World J Gastroenterol, 2012, 18(9):971978. ［13］ Wang BJ, Bao JJ, Wang JZ, et al. Immunostaining of PD1/PDLs in liver tissues of patients with hepatitis and hepatocellular carcinoma［J］. World J Gastroenterol, 2011, 17(28): 33223329. ［14］ Song S, Yuan P, Wu H, et al. Dendritic cells with an increased PDL1 by TGFβ induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells［J］. Int Immunopharmacol, 2014, 20(1) :117123. ［15］ Geng L, Deng J, Jiang G, et al. B7H1 upregulated expression in human hepatocellular carcinoma tissue:correlation with tumor interleukin10 levels［J］. Hepatogastroenterology, 2011, 58(107108): 960964. ［16］ Qin X, Liu C, Zhou Y, et al. Cisplatin induces programmed death1ligand 1(PDL1) overexpression in hepatoma H22 cells via Erk /MAPK signaling pathway［J］. Cell Mol Biol (Noisylegrand), 2010, 56 Suppl:OL13661372. ［17］ Shi F, Shi M, Zeng Z, et al. PD1 and PDL1 upregulation promotes CD8(+) Tcell apoptosis and postoperative recurrence in hepatocellular carcinoma patients［J］. Int J Cancer, 2011, 128(4): 887896. ［18］ Xylinas E, Robinson BD, Kluth LA, et al. Association of Tcell coregulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder［J］. Eur J Surg Oncol, 2014, 40(1):121127. ［19］ Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of antiPD1 antibody in cancer［J］. N Engl J Med, 2012, 366(26):24432454. ［20］ Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiPDL1 antibody in patients with advanced cancer［J］. N Engl J Med, 2012, 366(26):24552465.

程序性死亡受体-1及其配体在恶性肿瘤中的研究进展

Research update on PD1 and its ligand PDL1 in malignant tumor

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价